Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 2074-2084

  Amin, Shilu ^a   Walsh, Meagan ^a   Wilson, Caroline ^a   Parker, Anton E ^b   Oscier, David ^b   Willmore, Elaine ^c   Mann, Derek ^a   Mann, Jelena ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Chronic lymphocytic leukaemia; DNA methylation; Histone modifications; ZAP70

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DRUG DERIVATIVE; HISTONE; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE ZAP 70; ZAP70 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CELL LINE; CHEMISTRY; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOLOGY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING;

AZACITIDINE; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84863847397     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01503.x     Document Type: Article

References (50)

1. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94: 1848-54.
2. Zanotti R, Ambrosetti A, Lestani M, et al. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia. 2007; 21: 102-9.
3. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194: 1639-47.
4. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003; 101: 4944-51.
5. Elder ME, Hope TJ, Parslow TG, et al. Severe combined immunodeficiency with absence of peripheral blood CD8 + T cells due to ZAP-70 deficiency. Cell Immunol. 1995; 165: 110-7.
6. Zoller KE, MacNeil IA, Brugge JS. Protein tyrosine kinases Syk and ZAP-70 display distinct requirements for Src family kinases in immune response receptor signal transduction. J Immunol. 1997; 158: 1650-9.
7. Latour S, Chow LM, Veillette A. Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases. J Biol Chem. 1996; 271: 22782-90.
8. Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005; 105: 2036-41.
9. Gobessi S, Laurenti L, Longo PG, et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 2007; 109: 2032-9.
10. Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008; 111: 2685-92.
11. Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006; 107: 3584-92.
12. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008; 112: 1923-30.
13. Chantepie SP, Vaur D, Grunau C, et al. ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia. Leuk Res. 2010; 34: 800-8.
14. Corcoran M, Parker A, Orchard J, et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica. 2005; 90: 1078-88.
15. Milutinovic S, D'Alessio AC, Detich N, et al. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis. 2007; 28: 560-71.
16. Ou JN, Torrisani J, Unterberger A, et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol. 2007; 73: 1297-307.
17. Oakley F, Mann J, Nailard S, et al. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. Am J Pathol. 2005; 166: 695-708.
18. O'Neill LP, Turner BM. Immunoprecipitation of native chromatin: NChIP. Methods (San Diego, Calif.). 2003; 31: 76-82.
19. Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology. 2010; 138: 705-14, 14 e1-4.
20. Blum KA, Advani A, Fernandez L, et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol. 2009; 147: 507-14.
21. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005; 105: 959-67.
22. Kouzarides T. Chromatin modifications and their function. Cell. 2007; 128: 693-705.
23. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem. 2006; 75: 243-69.
24. Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol. 2008; 20: 341-8.
25. Sims RJ, 3rd, Reinberg D. Histone H3 Lys 4 methylation: caught in a bind? Genes Dev. 2006; 20: 2779-86.
26. Yan C, Boyd DD. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Mol Cell Biol. 2006; 26: 6357-71.
27. Bannister AJ, Schneider R, Myers FA, et al. Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. J Biol Chem. 2005; 280: 17732-6.
28. Weake VM, Workman JL. Inducible gene expression: diverse regulatory mechanisms. Nat Rev. 2010; 11: 426-37.
29. Zeng W, Ball AR Jr, Yokomori K. HP1: heterochromatin binding proteins working the genome. Epigenetics. 2010; 5: 287-92.
30. Schuettengruber B, Chourrout D, Vervoort M, et al. Genome regulation by polycomb and trithorax proteins. Cell. 2007; 128: 735-45.
31. Beisel C, Paro R. Silencing chromatin: comparing modes and mechanisms. Nat Rev. 2011; 12: 123-35.
32. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J. 2009; 50: 455-63.
33. Bernstein BE, Kamal M, Lindblad-Toh K, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005; 120: 169-81.
34. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007; 39: 311-8.
35. Kim TH, Barrera LO, Zheng M, et al. A high-resolution map of active promoters in the human genome. Nature. 2005; 436: 876-80.
36. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129: 823-37.
37. Vermeulen M, Mulder KW, Denissov S, et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell. 2007; 131: 58-69.
38. Okitsu CY, Hsieh JC, Hsieh CL. Transcriptional activity affects the H3K4me3 level and distribution in the coding region. Mol Cell Biol. 2010; 30: 2933-46.
39. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev. 2009; 10: 295-304.
40. Chen ZX, Mann JR, Hsieh CL, et al. Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. J Cell Biochem. 2005; 95: 902-17.
41. Ooi SK, Qiu C, Bernstein E, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature. 2007; 448: 714-7.
42. Suetake I, Shinozaki F, Miyagawa J, et al. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. J Biol Chem. 2004; 279: 27816-23.
43. Kn H, Bassal S, Tikellis C, et al. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL). Cancer Biol Ther. 2004; 3: 989-94.
44. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007; 7: 823-33.
45. Nightingale KP, Gendreizig S, White DA, et al. Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem. 2007; 282: 4408-16.
46. Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood. 2003; 102: 652-8.
47. Bhalla S, Balasubramanian S, David K, et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009; 15: 3354-65.
48. Inoue S, Riley J, Gant TW, et al. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia. 2007; 21: 1773-82.
49. Inoue S, MacFarlane M, Harper N, et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 2004; 11: S193-206.
50. Stamatopoulos B, Meuleman N, De Bruyn C, et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia. 2009; 23: 2281-9.